Ryan Haumschild, PharmD, MS, MBA, CPEL
Articles by Ryan Haumschild, PharmD, MS, MBA, CPEL

Understanding the Burden of Menopausal Vasomotor Symptoms
ByRyan Haumschild, PharmD, MS, MBA, CPEL,JoAnn V. Pinkerton, MD, FACOG, MSCP ,Alexa N. Fiffick, DO, MBS, MSCP ,Kamilia Smith, MD, FACOG, NCMP Panelists discuss how innovative neurokinin-targeted therapies for vasomotor symptoms can reshape menopause management and address unmet needs and improving patient outcomes while highlighting the importance of equity in treatment access.

Future Directions of BTK Inhibitors in Leukemia and Lymphoma
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD Experts discuss future directions of BTK inhibitors.

Patient Access Advocacy for BTK Inhibitors
ByRyan Haumschild, PharmD, MS, MBA, CPEL,Roy Beveridge, MD,Brian T. Hill, MD, PhD,Adam S. Kittai, MD A panel of specialists discuss patient access advocacy for BTK inhibitors.
Participating Faculty: Perspectives in Bronchiectasis Management
ByNauman Chaudary, MD,Francois Fadell, MD,Bryan Garcia, MD,Ryan Haumschild, PharmD, MS, MBA, CPEL,Margaret M. Johnson, MD,Rebecca C. Keith, MD,Diego J. Maselli, MD,George Solomon, MD,Kevin Winthrop, MD, MPH Clinical Perspectives in Bronchiectasis Management
ByNauman Chaudary, MD,Francois Fadell, MD,Bryan Garcia, MD,Ryan Haumschild, PharmD, MS, MBA, CPEL,Margaret M. Johnson, MD,Rebecca C. Keith, MD,Diego J. Maselli, MD,George Solomon, MD,Kevin Winthrop, MD, MPH Experts urge earlier CT diagnosis of bronchiectasis, focus on preventing exacerbations and improving quality of life, and call for US guidelines, approved therapies, and research.